Soranib 200mg 30’s Tablet

Soranib 200mg Tablet (Sorafenib Tosylate) is a multitargeted BRAF kinase inhibitor and VEGFR inhibitor approved for treating advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and differentiated thyroid cancer (DTC). Composition: Each tablet contains 200mg Sorafenib tosylate with pharmaceutical excipients. Indications: Sorafenib treats metastatic RCC, advanced unresectable HCC, locally recurrent or metastatic DTC, and potential BRAF-mutant melanoma. Clinical efficacy demonstrates improved overall survival in HCC (10.7 vs 7.9 months) and progression-free survival in RCC. Contraindications: Absolute contraindications include hypersensitivity, uncontrolled hypertension (>150/100), recent MI/stroke, severe hepatic impairment. Relative caution with cardiac arrhythmias, thrombosis history, GI perforation risk. Drug Interactions: Major with CYP3A4 inhibitors/inducers affecting levels, warfarin requiring INR monitoring, doxorubicin increasing cardiotoxicity risk. Dosage & Administration: Standard 400mg twice daily (two 200mg tablets); can reduce to 200mg BD for tolerability. Take on empty stomach 1 hour before/2 hours after meals. Storage: 15-30°C in original moisture-protective packaging. Side Effects: Common: hand-foot syndrome (38-60%), diarrhea, rash, hypertension (17-76%), fatigue, alopecia. Serious: cardiac ischemia, GI perforation, hepatotoxicity, arterial thromboembolism, myocardial infarction. Precautions: Baseline and monthly ECG; baseline and bi-weekly blood pressure monitoring; monthly LFTs; weekly for cardiac event signs; dermatology review for rash management. Pregnancy & Lactation: Teratogenic (Category D); absolutely contraindicated in pregnancy/lactation. Males require barrier contraception during therapy and 2 weeks post-treatment. Females require hormonal+barrier contraception with pregnancy testing baseline and monthly. Substitutes: Sunitinib, Pazopanib for RCC; lenvatinib for thyroid cancer; atezolizumab+bevacizumab for HCC. FAQs: Expected response 4-8 weeks; hand-foot syndrome management (hydration, emollients, reduced dosing); hypertension control critical; cost varies; intermittent dosing not recommended. Expected Timeline: Week 2 tolerability; Week 4 clinical assessment; Week 8 imaging (CT/ultrasound); Month 3 response evaluation (RECIST/mRECIST). Book Oncology Consultation: Essential for baseline risk stratification, toxicity management protocol, cardiac monitoring, and treatment modification. Schedule Tests: Baseline CBC, LFTs, coagulation, troponin, TSH; weekly BP; monthly LFTs; baseline and monthly ECG; monthly VEGFR mutation testing if applicable.